IT and cybersecurity for BioTech
You are held to HIPAA/FDA (subset) – and, like most firms your size, you are expected to meet it without anyone in-house whose job it is to own it. We run the IT and the security program so the obligation is actually covered, not just acknowledged.
Where we usually start: Research IP + investor/board pressure.
If this sounds familiar
“A security gap could cost us a partnership or our next round.”
Every pharma partnership, fundraise, or acquisition conversation now comes with a security questionnaire and diligence review, and leadership worries that a weak or undocumented IT posture will stall a deal, lower their valuation, or kill it outright.
“We can’t afford to lose our data or our IP.”
Years of research, proprietary formulations, genomic datasets, and clinical results represent the entire value of the company. The thought of ransomware, a breach, or simply losing irreplaceable data to a failed backup is an existential, not operational, concern – especially given that biotech IP is a known target for both criminals and nation-state actors.
“IT can’t be the thing that slows the science down.”
Leadership measures success in milestones hit and timelines met. Outages, login friction, lab-instrument connectivity problems, or onboarding delays for new scientists are intolerable because they directly burn runway and push back the data they need to raise money or advance a program.
Who this is for
Typical size: 50–250 employees. If that is roughly you, the rest of this page will land.
What working with us looks like
A named team that knows your stack, monitoring and patching that happens whether or not anyone chases it, and a written security program kept current – with the evidence to back it up when a client, an auditor or an insurer asks. We report to the COO / VP Ops / CFO, not to a ticket queue.
Talk to us
Call 206-850-1496 or email mhasse@itwerx.net and we will set up a short call – no audit, no pitch deck, just a conversation about what you have and what is worrying you.